Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2007 by National Institute of Allergy and Infectious Diseases (NIAID).
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00119405
First received: July 11, 2005
Last updated: February 22, 2010
Last verified: December 2007

July 11, 2005
February 22, 2010
April 2005
November 2010   (final data collection date for primary outcome measure)
  • Mitochondrial function [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]
  • mtDNA [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]
Not Provided
Complete list of historical versions of study NCT00119405 on ClinicalTrials.gov Archive Site
  • fat apoptosis [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]
  • limb fat [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]
  • oxidative markers [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
Not Provided
 
Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Role of Mitochondria in the Development of HIV Atrophy

Nucleoside reverse transcriptase inhibitors (NRTIs) are a class of anti-HIV drug that can be an important part of an HIV treatment regimen. Because anti-HIV therapy may have negative side effects, there is a great need to carefully study HIV infected patients on such regimens. One negative side effect observed in many HIV infected patients is lipoatrophy, a condition that results in fat loss in the body. It is unclear if NRTIs also have a role in the development of mitochondrial toxicity, a condition that affects the body's ability to produce energy. The purpose of this study is to observe the effects of an NRTI-based, protease inhibitor (PI)-sparing drug regimen on fat loss in HIV infected, treatment-naive adults.

Study hypothesis: The initiation of NRTI-containing, PI-sparing therapy will inhibit mitochondrial DNA (mtDNA) synthesis and lead to a decrease in mtDNA content in adipose tissue, skeletal muscle and peripheral blood mononuclear cells (PBMCs), will cause deterioration in mitochondrial function, will increase fat apoptosis and oxidative damage biomarkers, and will lead to progressive decrease in body fat content.

NRTIs are a mainstay of HIV treatment regimens, often part of initial treatment regimens for newly diagnosed patients. Recent data suggest that NRTIs are responsible for lipoatrophy, a condition marked by progressive fat loss. Another negative side effect to antiretroviral (ARV) regimens is mitochondrial toxicity, which can damage the heart, nerves, muscles, kidneys, pancreas and liver, as well as affecting the body's ability to produce energy for important life processes. It has been hypothesized that lipoatrophy may be related to mitochondrial toxicity, but a causal relationship between the two has yet to be established. This study will examine HIV infected treatment-naive patients who are initiating their first ARV regimens. The regimens will contain 2 NRTI, one of which being zidovudine and a non-nucleoside reverse transcriptase inhibitor (NNRTI). The regimens will not contain any PIs.

Patients will participate in this study for 96 weeks. There will be 4 study visits at Weeks 12, 24, 48, and 96. Dual-energy x-ray absorptiometry (DEXA) scans and fat biopsies will occur at all visits. Additionally, blood collection for metabolic testing will occur at Week 12. ARVs will not be provided by this study.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

Fat and Blood for mitochindrial DNA and different nuclear genes that regulate fat and lipid metabolism

Non-Probability Sample

HIV positive adults starting their first antiretroviral regimen with either AZT-containing combination

  • HIV Infections
  • Lipodystrophy
  • Metabolic Diseases
  • Nutrition Disorders
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
25
December 2010
November 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • HIV-1 infected
  • Treatment-naive
  • Plan to initiate first ARV regimen with 2 NRTIs and an NNRTI
  • Plan to include zidovudine as part of first ARV regimen

Exclusion Criteria:

  • Current use of steroids or growth hormone
  • Coagulopathies or other bleeding disorders
  • Pregnancy or breastfeeding
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00119405
1R01AI060484-01A2A, 1R01-AI060484-01A2A
No
Grace McComsey, MD, Case Western Reserve University
National Institute of Allergy and Infectious Diseases (NIAID)
Not Provided
Principal Investigator: Grace A. McComsey, MD University Hospital Case Medical Center
National Institute of Allergy and Infectious Diseases (NIAID)
December 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP